Invention Grant
US08664273B2 Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin
失效
在用聚乙二醇化干扰素α2A / 2B和利巴韦林治疗无反应的患者中用特拉匹韦（VX-950）治疗丙型肝炎病毒
- Patent Title: Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin
- Patent Title (中): 在用聚乙二醇化干扰素α2A / 2B和利巴韦林治疗无反应的患者中用特拉匹韦（VX-950）治疗丙型肝炎病毒
-
Application No.: US13153199Application Date: 2011-06-03
-
Publication No.: US08664273B2Publication Date: 2014-03-04
- Inventor: Lindsay McNair , John McHutchison
- Applicant: Lindsay McNair , John McHutchison
- Applicant Address: US MA Boston
- Assignee: Vertex Pharmaceuticals Incorporated
- Current Assignee: Vertex Pharmaceuticals Incorporated
- Current Assignee Address: US MA Boston
- Agency: Honigman Miller Schwartz & Cohn LLP
- Agent Noel E. Day; Jonathan P. O'Brien
- Main IPC: A61K38/21
- IPC: A61K38/21 ; A61K38/00 ; A61K31/14
Abstract:
The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.
Public/Granted literature
Information query
IPC分类:
